Drugs / LG00034053
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05237752 | Apr 2022 → Dec 2023 | osteoarthritis, knee | LG Chem | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-04 | LG Life Sciences | Regulatory LG Chem initiates clinical development of next-generation new drugs for treatment of arthritis lgchem.com ↗
development of new drug accelerated through approval of Phase 1b/2 clinical trials by the Ministry of Food and Drug Safety |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-04 | LG Life Sciences | LG Chem initiates clinical development of next-generation new drugs for treatment of arthritis lgchem.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LG00034053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05237752 ↗ |
| Action | Inhibit | “a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis” NCT05237752 ↗ |